MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.

被引：0
|
作者：
Nastoupil, Loretta J.
Song, Yuqin
Sehn, Laurie Helen
Sarkozy, Clementine
Zinzani, Pier Luigi
Silvestre, Antonio Salar
Zhang, Jun
Huang, Sha
Wang, Julie
Delarue, Richard
Trotman, Judith
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[3] Univ British Columbia, Vancouver, BC, Canada
[4] Inst Curie, Paris, France
[5] Univ Bologna, Bologna, Italy
[6] Hosp del Mar, Barcelona, Spain
[7] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[8] BeiGene USA Inc, San Mateo, CA USA
[9] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[10] Univ Sydney, Concord Repatriat Gen Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7590
引用
收藏
页数：1
相关论文
共 50 条
  • [31] RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.
    Fowler, Nathan Hale
    Morschhauser, Franck
    Feugier, Pierre
    Bouabdallah, Reda
    Tilly, Herve
    Palomba, Maria Lia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Subcutaneous Epcoritamab With Rituximab plus Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
    Falchi, Lorenzo
    Leppa, Sirpa
    Wahlin, Bjorn E.
    Nijland, Marcel
    Christensen, Jacob Haaber
    De Vos, Sven
    Holte, Harald
    Linton, Kim M.
    Abbas, Aqeel
    Wang, Liwei
    Dinh, Minh
    Elliott, Brian
    Belada, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S392 - S392
  • [33] CURRENT EPCORITAMAB PLUS RITUXIMAB AND LENALIDOMIDE (R2) PERCEPTIONS FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
    Levine, E.
    Gentile, D.
    Swain, R.
    Bone, R. N.
    Jennings-Zhang, L.
    Jeune-Smith, Y.
    Feinberg, B.
    VALUE IN HEALTH, 2024, 27 (12) : S342 - S342
  • [34] The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial
    Shi, Yuankai
    Qin, Yan
    Song, Yongping
    Zhou, Keshu
    Zhou, Hui
    Jing, Hongmei
    Xiang, Ying
    Wang, Zhao
    Wang, Zhen
    Zang, Aimin
    Bai, Ou
    Li, Zhenyu
    Zhang, Huilai
    BLOOD, 2021, 138
  • [35] Evaluation of response to anti-CD20 (Rituximab) trial in relapsed follicular lymphoma after six years in follow-up.
    Rubio-Martinez, A
    Palomera, L
    Recasens, V
    Najera, MJ
    Perella, M
    Puente, F
    Perdiguer, L
    Rubio-Felix, D
    Mayayao, P
    Giraldo, P
    BLOOD, 2005, 106 (11) : 276B - 276B
  • [36] Radioimmunotherapy with 131I anti-CD20 chimeric monoclonal antibody (rituximab) for relapsed or refractory non-Hodgkins lymphoma.
    Turner, JH
    Martindale, A
    Claringbold, PG
    Boucek, J
    Leahy, MF
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 115P - 116P
  • [37] Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
    Coiffier, Bertrand
    Osmanov, Evgenii A.
    Hong, Xiaonan
    Scheliga, Adriana
    Mayer, Jiri
    Offner, Fritz
    Rule, Simon
    Teixeira, Adriana
    Walewski, Jan
    de Vos, Sven
    Crump, Michael
    Shpilberg, Ofer
    Esseltine, Dixie-Lee
    Zhu, Eugene
    Enny, Christopher
    Theocharous, Panteli
    van de Velde, Helgi
    Elsayed, Yusri A.
    Zinzani, Pier Luigi
    LANCET ONCOLOGY, 2011, 12 (08): : 773 - 784
  • [38] Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
    Batlevi, Connie Lee
    Park, Steven I.
    Phillips, Tycel Jovelle
    Amengual, Jennifer
    Andorsky, David Jacob
    Campbell, Philip
    Mckay, Pamela
    Leonard, John Paul
    Sondhi, Manu
    Yang, Jay
    Chen, Yingxue
    O'Connor, Heather
    Slatcher, Pamela
    Morschhauser, Franck
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
    Morschhauser, F.
    Marlton, P.
    Vitolo, U.
    Linden, O.
    Seymour, J. F.
    Crump, M.
    Coiffier, B.
    Foa, R.
    Wassner, E.
    Burger, H. -U.
    Brennan, B.
    Mendila, M.
    ANNALS OF ONCOLOGY, 2010, 21 (09) : 1870 - 1876
  • [40] Follow-up during four years after anti CD20 (Rituximab) trial in relapsed Follicular Lymphoma.
    Giraldo, P
    Pelegrin, F
    Palomera, L
    Mayayo, P
    Najera, MJ
    Perdiguer, L
    Puente, F
    Rubio-Félix, D
    BLOOD, 2003, 102 (11) : 302B - 303B
12345